# Retrograde Inflammatory Signaling from Neutrophils to Endothelial Cells by Soluble Interleukin-6 Receptor Alpha

Vijayanand Modur,\*\* Yujie Li,\* Guy A. Zimmerman,\*§ Stephen M. Prescott,§ and Thomas M. McIntyre\*\*§

\*Nora Eccles Harrison Cardiovascular Research and Training Institute, <sup>‡</sup>Division of Experimental Pathology, <sup>§</sup>Department of Medicine, and <sup>¶</sup>Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84112

# Abstract

Endothelial cells initiate the inflammatory response by recruiting and activating leukocytes. IL-6 is not an agonist for this, but we found soluble IL-6 receptor  $\alpha$ -subunit (IL-6R $\alpha$ ), with their constitutive IL-6 synthesis, stimulated endothelial cells to synthesize E-selectin, intracellular adhesion molecule-1, vascular cellular adhesion molecule-1, IL-6, and IL-8, and to bind neutrophils. Neutrophils express significant amounts of IL-6R $\alpha$  and upon stimulation shed it: this material activates endothelial cells through a newly constituted IL-6 receptor. Retrograde signaling from PMN activated in the extravascular compartment to surrounding endothelial cells will recruit more and a wider variety of leukocytes. The limiting signal is a soluble receptor, not a cytokine. (*J. Clin. Invest.* 1997. 100:2752–2756.) Key words: inflammation • leukocyte • E-selectin • interleukin-8 • chemokine

## Introduction

Endothelium is the gatekeeper of the inflammatory response: it attracts and activates leukocytes when endothelial cells are appropriately stimulated (1). Marginated leukocytes rapidly migrate to the extravascular space where exposure to additional stimuli causes release of reactive oxygen species and proteolytic enzymes (2, 3). One consequence of the destructive environment surrounding activated PMN is the shedding of surface proteins such as L-selectin (4) and TNF receptors (5). The functional consequence of this self-induced loss of surface proteins is not clear as this occurs after migration into the extravascular compartment and full activation.

Neutrophils and monocytes express receptors for IL-6 consisting of a cytokine-binding alpha subunit  $(IL-6R\alpha)^1$  and a homodimer of transmembrane, signaling gp130 subunits (6). Receptors for other members of the IL-6 family also contain the signaling gp130 subunit and combinations of cytokine-specific  $\alpha$ -subunits and gp130-related subunits. Monocytes and COS-7

J. Clin. Invest.

cells expressing recombinant IL-6Ra shed a portion of this receptor in response to the pleiotrophic agonist PMA in a form able to bind cytokine and stimulate gp130 signaling (7, 8). IL-6 alone does not activate endothelial cells (although there is a single report to the contrary [9]) even though oncostatin M, a related family member whose receptor contains gp130 (10), does activate the inflammatory response of these cells (11). This result would be expected should endothelial cells lack IL-6Ra. Since truncated, soluble IL-6Ra can confer IL-6 sensitivity to cells containing gp130 (12), including endothelial cells (13), we determined whether a complex of IL-6 and sIL-6Ra activated the inflammatory response of human endothelial cells. We found this complex did stimulate the inflammatory response. However, more striking was that the addition of sIL-6R $\alpha$  alone activated endothelial cells: it appears constitutive endothelial cell IL-6 expression was sufficient to form an active complex with exogenous soluble receptor. Endothelial cell activation depended on the concentration of sIL-6R $\alpha$ , showing the solublized receptor was the limiting component of the signaling process. This observation is relevant as we found PMN exposed to the bacterial peptide FMLP shed IL-6R $\alpha$  in sufficient quantities to activate the inflammatory response of endothelial cells. These results suggest that ablumenal neutrophil degranulation and cell surface protein shedding could send a retrograde signal back through the endothelium to recruit more inflammatory cells from the circulation.

### Methods

Materials. HBSS and M199 were from Whittaker Bioproducts (Walkersville, MD) and human serum albumin was from Miles Laboratories (Elkhart, IN.) Tissue culture plates were from Costar Data Packaging Corp. (Cambridge, MA). Polyclonal rabbit anti-human IL-8, IL-6Ra, gp130, and E-selectin (BBA-8) antibodies , and recombinant human oncostatin M, gp130, sIL-6Ra, and TNF were from R&D systems (Minneapolis, MN). Endogen (Boston, MA) supplied polyclonal rabbit anti-human IL-6 and Biosource International (Camarillo, CA) supplied recombinant human IL-6. Anti-human vascular cellular adhesion molecule-1 (VCAM-1), intracellular adhesion molecule-1 (ICAM-1), and IL-6 (see Fig. 2) were from PharMingen (San Diego, CA.) Bachem (Torrence, CA) supplied IL-688-121. ECL Western blotting reagents were purchased from Amersham Corp. (Arlington Heights, IL). All secondary antibodies were obtained from Biosource International. Other reagents were from Sigma Chemical Co. (St. Louis, MO).

*Cell isolation and culture.* Human umbilical vein endothelial cells were cultured in 24- or 35-mm multiwell plates as described (14). Only monolayers of primary cultures that were tightly confluent (24 h postconfluence) were used for these studies. Routine cultures show < 1% contamination with CD45<sup>+</sup> cells. Neutrophils were isolated from EDTA-anti–coagulated human blood and labeled with <sup>111</sup>Inoxine for adhesion to a gelatinized surface or activated endothelial cells as described (15).

Endothelial cell activation. Medium was removed from postconfluent endothelial cells, and agonist in Hank's balanced salt solution

Address correspondence to Thomas McIntyre, Nora Eccles Harrison CVRTI, Building 500, 95 S. 2000E. 13 ACK, University of Utah, Salt Lake City, UT 84112. Phone: 801-581-8183; FAX: 801-581-3128; E-mail: mcintyre@cvrti.utah.edu

Received for publication 18 April 1997 and accepted in revised form 16 September 1997.

<sup>1.</sup> Abbreviations used in this paper: IL-6R $\alpha$ , IL-6 receptor  $\alpha$ -subunit; sIL-6R $\alpha$ , soluble IL-6R $\alpha$ .

<sup>©</sup> The American Society for Clinical Investigation, Inc. 0021-9738/97/12/2752/05 \$2.00 Volume 100, Number 11, December 1997, 2752–2756 http://www.jci.org


containing 0.5% human serum albumin (HBSS/A) was added for the stated time. Polymyxin B did not affect any parameter we examined, so it was routinely used at 10  $\mu$ g/ml during cell stimulation. When the effect of anti–IL-6, anti-gp130, or IL-6<sub>88-121</sub> was examined, they were preincubated with endothelial cells for 90 min. In some experiments medium was removed from the monolayers and they were incubated for 24 h in HBSS/A before the cells were washed three times with HBSS/A. Supernatants were removed from incubated monolayers after 4 h for ELISA determination of IL-8 or IL-6, while the monolayers were used to quantitate inflammatory protein synthesis or PMN adhesion.

ELISA, flow cytometry, and Western blotting. Material for Western blots was collected by solubilizing monolayers with boiling Laemmli (16) sample buffer without  $\beta$ -mercaptoethanol. Proteins were electrophoretically separated under nonreducing conditions in 7.5% SDS polyacrylamide gels and then transferred to Immobilon membranes (Millipore, Bedford, MA). The membrane was blocked with 5% nonfat milk in Tris-buffered saline with 0.05% Tween-20 (TBST), and probed with 1 µg/ml anti-E-selectin monoclonal antibody. Horseradish peroxidase-conjugated streptavidin (1:5,000) in the presence of 100 µg/ml nonimmune rabbit IgG in TBST was detected by ECL. IL-6 and IL-8 were quantitated from endothelial cell supernatants by sandwich ELISA with polyclonal rabbit anti-human antibody; detection used biotinylated rabbit anti-human IL-6 or IL-8, and streptavidin-conjugated horseradish peroxidase (17). Endothelial cells were released from the culture dish with a brief trypsin treatment, washed in goat serum, and stained for surface ICAM-1 or VCAM-1 (17).

*PMN shedding.* PMN ( $5.5 \times 10^{6}$ /ml) were incubated (30 min;  $37^{\circ}$ C) with  $10^{-6}$  M FMLP, PMA ( $10^{-6}$  M), or buffer and then centrifuged (1,000 g, 5 min). Anti–IL-6R $\alpha$  (25 µg/ml) or soluble gp130 ( $10 \mu$ g/ml) was added to some supernatant aliquots (30 min preincubation at  $37^{\circ}$ C) to block receptor function. In addition, some monolayers were pretreated for 30 min at  $37^{\circ}$ C with anti-gp130 ( $50 \mu$ g/ml). Endothelial cells were incubated for 4 h at  $37^{\circ}$ C with PMN supernatants (1 ml/well) before E-selectin expression was determined by Western blotting.

#### Results

sIL-6R $\alpha$  activates endothelial cells to bind PMN. Oncostatin M, but not its family member IL-6, activated endothelial cells to bind quiescent PMN (Fig. 1 A). This shows that endothelial cells possess functional gp130, which is common to both oncostatin M and IL-6 receptors (10), and suggests these cells lack the IL-6R $\alpha$  subunit of the IL-6 receptor that binds IL-6. We analyzed surface IL-6R $\alpha$  expression by flow cytometry and mRNA levels by reverse transcriptase-PCR, which confirmed that the insensitivity to IL-6 reflects a lack of this receptor component (see Fig. 4A). Consistent with this, we found that addition of a complex of IL-6 and a truncated, soluble form of the alpha subunit (sIL-6R $\alpha$ ) activated endothelial cell-dependent PMN adhesion (Fig. 1 A). Polymyxin B did not affect any of these responses, so endotoxin was not responsible for this stimulation. In a surprising result, we found that sIL-6R $\alpha$ alone was just as effective an agonist as the preformed complex of cytokine and its soluble receptor (Fig. 1A). Moreover, we found that PMN adhesion to the activated endothelial cells was dependent on the concentration of sIL-6R $\alpha$  (Fig. 1 *B*). Thus the soluble receptor was the limiting component under these conditions. PMN adhesion was an endothelial celldependent process as sIL-6Ra or IL-6 failed to stimulate PMN in the absence of endothelial cells (control,  $6\pm 2\%$ ; 1 µg/ml sIL-6sR, 6±1%; 100 ng/ml IL-6, 10±3%; 10<sup>-8</sup> M FMLP,  $38\pm0\%$  PMN bound to a gelatinized surface as a measure of CD11b/CD18 effectiveness [18]).



*Figure 1.* sIL-6R $\alpha$  activates endothelial cell-dependent PMN adhesion. (*A*) Endothelial cells were incubated with oncostatin M (100 ng/ml), IL-6 (100 ng/ml), sIL-6R $\alpha$  (1 µg/ml), both IL-6 and sIL-6R $\alpha$ , or TNF $\alpha$  (500 U/ml) for 4 h. <sup>111</sup>In-PMN adhesion to the monolayers during a 5-min period was quantitated as a percentage of total unactivated PMN added. (*B*) Endothelial cells were incubated with the stated concentrations of sIL-6R $\alpha$  for 4 h and <sup>111</sup>In-PMN adhesion was determined as before. The values shown are mean and range of duplicate determinations and are representative of two experiments.

sIL-6Ra activates endothelial cell inflammatory protein synthesis. We found (Fig. 2 A) that sIL-6R $\alpha$  induced the expression of the PMN-binding protein E-selectin. Induction of E-selectin synthesis and accumulation was blocked by an inhibitory IL-6 antibody, by an antibody to the gp130 receptor subunit common to IL-6 and oncostatin M receptors, and by a synthetic peptide fragment of IL-6 that competitively blocks IL-6 binding to the soluble receptor (19). The anti-gp130 antibody also suppressed on costatin M, but not  $TNF\alpha$ , stimulation of E-selectin synthesis (not shown). We found that sIL-6R $\alpha$ also stimulated the expression of the proinflammatory counterligand ICAM-1 (Fig. 2 B), and that it stimulated surface expression of the monocyte-binding protein VCAM-1 (Fig. 2C). sIL-6Rα also induced the synthesis of the inflammatory C-X-C chemokine IL-8 (Fig. 3 A), and, interestingly, it induced the synthesis of more IL-6 (Fig. 3 *B*). We conclude sIL-6R $\alpha$  activates endothelial cell inflammatory functions through endothelial cell-derived IL-6 and the gp130 subunits of the IL-6 holoreceptor normally present as a component of the oncostatin M receptor.

*PMN shed IL-6R\alpha upon activation*. Resting human neutrophils, unlike endothelial cells (Fig. 4*A*), abundantly express IL-6R $\alpha$  on their surface (Fig. 4*B*), but its expression is labile.





Figure 2. sIL-6Ra stimulates endothelial cell expression of adhesion proteins. (A) E-selectin expression. Endothelial cells were preincubated with buffer, anti-gp130 (50 µg/ml), anti-IL-6 (PharMingen, 1 µg/ml), or the synthetic IL-688-121 fragment (5 µg/ml) for 90 min and then incubated in the presence of the reagents with or without sIL-6Ra (1 µg/ ml) for 4 h. E-selectin was assayed by immunoblotting as described in Methods. (B) Expression of ICAM-1 and (C)VCAM-1 by control or sIL-6Rα-activated endothelial cells was analyzed by flow cytometry using nonimmune mouse IgG to determine nonspecific staining. The data presented are one of two experiments with similar results.

We found that expression of this receptor subunit was significantly reduced after exposure to FMLP or phorbol myristate acetate. This loss of surface IL-6R $\alpha$  correlated with a decrease in surface L-selectin expression (20), suggesting sIL-6R $\alpha$  may be shed from activated PMN in a similar fashion (8).

Shed sIL-6R $\alpha$  activates endothelial cells. We determined whether sIL-6R $\alpha$  was shed from activated neutrophils in sufficient quantities to stimulate endothelial cells. We treated PMN with buffer or FMLP for 30 min, removed the PMN, and then exposed endothelial cell monolayers to these supernatants. Supernatants from FMLP-activated neutrophils stimulated endothelial cell E-selectin synthesis, while supernatants from unstimulated neutrophils did not (Fig. 5). FMLP carryover did not account for this as FMLP itself did not induce E-selectin synthesis. Anti–IL-6R $\alpha$  antibody, anti-gp130 antibody, or competing soluble gp130 inhibited over half the E-selectin expression (Fig. 5). Ligation of the receptor complex by anti-gp130 evoked a small increase in E-selectin expression, while soluble gp130, which is shed in a less facile fashion than the alpha subunit (21), failed to induce E-selectin synthesis. Thus a functional IL-6 receptor can be assembled on endothelial cells using solubilized alpha subunits shed from activated neutrophils, and this de novo receptor stimulates the inflammatory response of endothelial cells.


# Discussion

IL-6 is considered to be an inflammatory cytokine, although it was not known to participate in the earliest phases of the inflammatory reaction where endothelial cells, PMN, and monocytes interact. Endothelial cells do not respond to IL-6 as they lack the cytokine-binding alpha subunit of the receptor ([22], Fig. 4 *A*). A remarkable property of the IL-6 receptor is that the nonsignaling alpha subunit can be exogenously supplied in




*Figure 3.* sIL-6R $\alpha$  induces cytokine secretion from endothelial cells. Endothelial cells were incubated with sIL-6R $\alpha$  (1 µg/ml), TNF (100 U/ml), or oncostatin M (1 µg/ml) for 4 h. Supernatants were collected and (*A*) IL-8 and (*B*) IL-6 concentrations were assayed by sandwich ELISA. Values are mean and range of duplicate determinations, and are representative of three experiments.

Endothelial cell IL-6 Receptor alpha subunit



PMN IL-6 Receptor alpha subunit




*Figure 4.* IL-6R $\alpha$  is shed from activated PMN. (*A*) Endothelial cells. Endothelial cells were removed from their growth plates and stained with nonimmune control or anti–IL-6R $\alpha$  for flow analysis. (*B*) PMN were treated with buffer, PMA (10<sup>-6</sup> M), or FMLP (1  $\mu$ M) for 30 min and surface IL-6R $\alpha$  was analyzed by flow cytometry using goat anti–human anti–IL-6R $\alpha$ . Background antibody staining was determined with nonimmune goat IgG.

a soluble form and still confer specific cytokine sensitivity (12, 23). We found that soluble IL-6R $\alpha$  recruited gp130 from the very large (> 110,000 receptors per cell [24]) pool of endothelial cell oncostatin M receptors and allowed it to mimic proinflammatory effects of TNF $\alpha$ . An unexpected finding in this regard was that sIL-6R $\alpha$  did not require the addition of exogenous IL-6 to activate these cells. Endothelial cell-derived IL-6, which is constitutively synthesized at low levels, was essential for this activation, but the most significant aspect of this is that the inflammatory response varied as a function of sIL-6 $\alpha$  concentration. Thus the agonist to which primary, but not multiply passed (22), endothelial cells respond in a graded fashion is the soluble receptor, not the cytokine. Previously, the role of sIL-6Rα has appeared to be mundane as its transgenic overexpression simply increases the half-life of IL-6 in the circulation and sensitizes animals to an acute phase response (25). Our data show that it can function as a true proinflammatory cytokine where its levels control endothelial cell function.

Inflammatory signaling is a vectoral process where stimulated endothelial cells recruit leukocytes from the circulation to the extravascular compartment. To this end endothelial cells synthesize and secrete several members of the C-X-C and C-C class of chemokines that activate neutrophils and monocytes, respectively. Few PMN products can reverse the flow of information and activate endothelial cells: although eventually cytokines synthesized by PMN (26) or massive free radical production by activated PMN (27, 28) might do so. Here we show that IL-6R $\alpha$  is rapidly shed from FMLP-activated PMN in sufficient quantities to allow activated PMN to efficiently stimulate endothelial cells. Proteolytic shedding of external surface proteins after activation serves uncertain purposes (29), although modification of adhesion is clearly one such function (4). The IL-6 receptor is shed from monocytes stimulated with the potent tumor promoter PMA and, as we show here, is shed from PMN after activation by a relevant, pathophysiologic agonist, FMLP. The role of IL-6 receptors on neutrophils has not been well defined, although it weakly induces platelet-activating factor synthesis (30) and weakly synergizes with TNF to enhance the respiratory burst (31). One outcome of our data is that the target of IL-6 signaling is not just the PMN expressing the IL-6 receptor, but also adjacent cells. This receptor then may be a sensitive environmental reporter that reverses signal flow by enabling proximal endothelial cells to respond to activated PMN.

Soluble IL-6R $\alpha$  may be a particularly relevant proinflammatory mediator following bacterial invasion. PMN exposed to the bacterial product FMLP (above), or monocytes exposed to pore-forming exotoxins (32) or bacterially derived metalloproteinases (33) shed their IL-6 receptor. Also, circulating sIL-6R $\alpha$  increases during sepsis (34), HIV infection (35), and reperfusion injury (36), although a part of this is due to mRNA alternative splicing (37). Recent data show the influx of PMN into inflamed joints correlates with the increased concentration of sIL-6R $\alpha$  in synovial fluid (38), and that sIL-6R $\alpha$  can act as a paracrine mediator localized to its site of generation (39). We show sufficient amounts of sIL-6R $\alpha$ , and potentially other unidentified endothelial cell agonists, can be released from activated PMN to induce the endothelial cell inflammatory re-



*Figure 5.* sIL-6R $\alpha$  shed from activated PMN stimulates endothelial cell E-selectin synthesis. Supernatants from buffer-treated PMN (*C*) or FMLP-treated PMN (*f*) were prepared as described in Methods. An aliquot of supernatants from stimulated or unstimulated PMN was incubated (50 µg/ml) with anti–IL-6R $\alpha$  or soluble gp130 (*sol-gp130*) for 60 min. Meanwhile endothelial cells were preincubated with anti-gp130 (50 µg/ml) or buffer for 90 min. The monolayers were then incubated (in the continued presence of the antibody if used) with buffer, PMN supernatants, or FMLP (1 µM) for 4 h. Cell lysates were prepared and E-selectin expression was determined by immunoblotting. The data are representative of two experiments.

sponse. This will occur after extravasated PMN find appropriate stimuli in the extravascular compartments, so pathfinding PMN can locally recruit more leukocytes from the circulation through retrograde activation of adjacent endothelial cells. Consistent with this model, the absence of IL-6 in homozygous knockout mice reduces the number of leukocytes recruited by extravascular stimuli by half (22). This shows that IL-6 and its receptor are not unique proinflammatory mediators, but do have major effects on the early steps in inflammation by assisting and strengthening the primary response to inflammatory stimuli.

## Acknowledgments

We thank Aaron Ponstler for technical assistance and Donnelle Benson, Deborah Dykstra, Ruth Ann Green, Margaret Vogel, and Wen Hua Li for leukocyte isolation and endothelial cell culture. We also thank Andrew Weyrich for careful reading of the manuscript, Diana Lim for figure preparation, and Denise Robinson for aid with the manuscript.

A grant from the National Cancer Institute (CA42014) and the Huntsman Cancer Institute supported the flow analysis core facility. This work was supported by National Institutes of Health (HL-50513, HL-44525), and the Nora Eccles Treadwell Foundation.

#### References

1. Zimmerman, G.A., T.M. McIntyre, and S.M. Prescott. 1996. Perspectives series: cell adhesion in vascular biology. J. Clin. Invest. 98:1699–1702.

2. Yee, J., B. Giannias, B. Kapadia, L. Chartrand, and N.V. Christou. 1994. Exudative neutrophils. *Arch. Surg.* 129:99–105.

3. Zimmerli, W., B. Seligmann, and J. Gallin. 1986. Exudation primes human and guinea pig neutrophils for subsequent responsivesmess to the chemotactic peptide *N*-formylmethionylleucylphenylalanine and increases complement component C3bi receptor expression. *J. Clin. Invest.* 77:925–933.

4. Kishimoto, T.K., M.A. Jutila, E.L. Berg, and E.C. Butcher. 1989. Neutrophil Mac-1 and MEL-14 adhesion proteins inversely regulated by chemotactic factors. *Science*. 245:1238–1241.

5. Porteu, F., and C. Nathan. 1990. Shedding of tumor necrosis factor receptors by activated human neutrophils. J. Exp. Med. 172:599–607.

6. Hibi, M., M. Murakami, M. Saito, T. Hirano, T. Taga, and T. Kishimoto. 1990. Molecular cloning and expression of an IL-6 signal transducer, gp130. *Cell.* 63:1149–1157.

7. Mullberg, J., H. Schooltink, T. Stoyan, M. Gunther, L. Graever, G. Buse, A. Mackiewicz, P.C. Heinrich, and S. Rose-John. 1993. The soluble interleukin-6 receptor is generated by shedding. *Eur. J. Immunol.* 23:473–480.

 Mullberg, J., F.H. Durie, C. Otten-Evans, M.R. Alderson, S. Rose-John,
D. Cosman, R.A. Black, and K.M. Mohler. 1995. A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J. Immunol. 155:5198–5205.

9. Watson, C., S. Whittaker, N. Smith, A.J. Vora, D.C. Dumonde, and K.A. Brown. 1996. IL-6 acts on endothelial cells to preferentially increase their adherence for lymphocytes. *Clin. Exp. Immunol.* 105:112–119.

10. Mosley, B., C. De Imus, D. Friend, N. Boiani, B. Thoma, L.S. Park, and D. Cosman. 1996. Dual oncostatin M (OSM) receptors. *J. Biol. Chem.* 271: 32635–32643.

11. Modur, V., M.J. Feldhaus, A.S. Weyrich, D.L. Jicha, S.M. Prescott, G.A. Zimmerman, and T.M. McIntyre. 1997. Oncostatin M is a proinflammatory mediator: in vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules. *J. Clin. Invest.* 100:158–168.

12. Economides, A.N., J.V. Ravetch, G.D. Yancopoulos, and N. Stahl. 1995. Designer cytokines: Targeting actions to cells of choice. *Science*. 270:1351–1353.

13. Hooper, W.C., D.J. Phillips, and B.L. Evatt. 1997. Endothelial cell protein S synthesis is upregulated by the complex of IL-6 and soluble IL-6 receptor. *Thromb. Haemost.* 77:1014–1019.

14. Zimmerman, G.A., T.M. McIntyre, and S.M. Prescott. 1985. Thrombin stimulates the adherence of neutrophils to human endothelial cells in vitro. *J. Clin. Invest.* 76:2235–2246.

15. Smiley, P.L., K.E. Stremler, S.M. Prescott, G.A. Zimmerman, and T.M. McInytre. 1991. Oxidatively fragmented phosphatidylcholines activate human neutrophils through the receptor for platelet-activating factor. *J. Biol. Chem.* 266:11104–1110.

16. Laemmli, U.K. 1970. Cleavage of structural proteins during the assem-

bly of the head of bacteriophage T4. Nature. 227:680-685.

17. Modur, V., G.A. Zimmerman, S.M. Prescott, and T.M. McIntyre. 1996. Endothelial cell inflammatory responses to  $TNF\alpha$ : ceramide-dependent and -independent mitogen-activated protein kinase cascades. *J. Biol. Chem.* 271: 13094–13102.

18. Zimmerman, G.A., and T.M. McIntyre. 1988. Neutrophil adherence to human endothelium in vitro occurs by CDw18 (Mo1, MAC-1/LFA-1/GP 150,95) glycoprotein-dependent and -independent mechanisms. *J. Clin. Invest.* 81:531–537.

19. Ekida, T., C. Nishimura, S. Masuda, S. Itoh, I. Shimada, and Y. Arata. 1992. A receptor-binding peptide from human interleukin-6: Isolation and a proton nuclear magnetic resonance study. *Biochem. Biophys. Res. Commun.* 189:211–220.

20. Lorant, D.E., R.P. McEver, T.M. McIntyre, K.L. Moore, S.M. Prescott, and G.A. Zimmerman. 1995. Activation of polymorphonuclear leukocytes reduces their adhesion to P-selectin and causes redistribution of ligands for P-selectin on their surfaces. *J. Clin. Invest.* 96:171–182.

21. Mullberg, J., E. Dittrich, L. Graeve, C. Gerhartz, K. Yasukawa, T. Taga, T. Kishimoto, P.C. Heinrich, and S. Rose-John. 1993. Differential shedding of the two subunits of the interleukin-6 receptor. *FEBS Lett.* 332:174–178.

22. Romano, M., M. Sironi, C. Toniatti, N. Polentarutti, P. Fruscella, P. Ghezzi, R. Faggioni, W. Luini, V. van Hinsbergh, S. Sozzani, et al. 1997. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. *Immunity*. 6:315–325.

23. Mullberg, J., H. Schooltink, T. Stoyan, M. Gunther, L. Graeve, G. Buse, A. Mackiewiez, P.C. Heinrich, and S. Rose-John. 1993. The soluble interleukin-6 receptor is generated by shedding. *Eur. J. Immunol.* 23:473–480.

24. Brown, T.J., J.M. Rowe, L. Jingwen, and S. Mohammed. 1991. Regulation of IL-6 expression by oncostatin M. J. Immunol. 147:2175–2180.

25. Peters, M., S. Jacobs, M. Ehlers, P. Vollmer, J. Mullberg, E. Wolf, G. Brem, K.H. Meyer sum Bushchenfelde, and S. Rose-John. 1996. The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J. Exp. Med. 183:1399–1406.

26. Cassatella, M.A. 1995. The production of cytokines by polymorphonuclear neutrophils. *Immunol. Today.* 16:21–26.

27. Lewis, M.S., R.E. Whatley, P. Cain, T.M. McIntyre, S.M. Prescott, and G.A. Zimmerman. 1988. Hydrogen peroxide stimulates the synthesis of platelet-activating factor by endothelium and induces endothelial cell-dependent neutrophil adhesion. *J. Clin. Invest.* 82:2045–2055.

28. Kurose, I., L.W. Argenbright, R. Wolf, and D.N. Granger. 1996. Oxidative stress during platelet-activating factor-induced microvascular dysfunction. *Microcirculation*. 3:401–410.

29. Tedder, T.F. 1991. Cell-surface receptor shedding: a means of regulating function. *Am. J. Respir. Cell. Mol. Biol.* 5:305–306.

30. Biffl, W.L., E.E. Moorte, F.A. Moore, Jr., C.C. Barnett, C.C. Silliman, and V.M. Peterson. 1996. Interleukin-6 stimulates neutrophil production of platelet-activating factor. J. Leukocyte Biol. 59:569–574.

31. Mullen, P.G., A.C. Windsor, C.J. Walsh, A.A. Fowler III, and H.J. Sugerman. 1995. Tumor necrosis factor-alpha and interleukin-6 selectively regulate neutrophil function in vitro. *J. Surg. Res.* 58:124–130.

32. Walev, I., P. Vollmer, M. Palmer, S. Bhakdi, and S. Rose-John. 1996. Pore-forming toxins trigger shedding of receptors for interleukin 6 and lipopolysaccharide. *Proc. Natl. Acad. Sci. USA*. 93:7882–7887.

33. Vollmer, P., I. Walev, S. Rose-John, and S. Bhakdi. 1996. Novel pathogenic mechanism of microbial metalloproteinases: liberation of membraneanchored molecules in biologically active form exemplified by studies with the human interleukin-6 receptor. *Infect. Immun.* 64:3646–3651.

34. Zeni, F., B. Tardy, M. Vindimian, P. Pain, P. Gery, and J.C. Bertrand. 1995. Soluble interleukin-6 receptor in patients with severe sepsis. *J. Infect. Dis.* 172:607–608.

35. Honda, M., S. Yamamoto, M. Cheng, K. Yasukawa, H. Suzuki, T. Saito, Y. Osugi, T. Tokunaga, and T. Kishimoto. 1992. Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. *J. Immunol.* 148:2175–2180.

36. Kukielka, G.L., C.W. Smith, A.M. Manning, K.A. Youker, L.H. Michael, and M.L. Entman. 1995. Induction of interleukin-6 synthesis in the myocardium. Potential role in postreperfusion inflammatory injury. *Circulation*. 92:1866–1875.

37. Horiuchi, S., Y. Koyanagi, Y. Zhou, H. Miyamoto, Y. Tanake, M. Waki, A. Matsumoto, M. Yamamoto, and N. Yamamoto. 1994. Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. *Eur. J. Immunol.* 24:1945–1948.

38. Desgeorges, A., C. Gabay, P. Silacci, D. Novick, P. Roux-Lombard, G. Grau, J.M. Dayer, T. Vischer, and P.A. Guerne. 1997. Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. *J. Rheumatol.* 24:1510–1516.

39. Peters, M., M. Odenthal, P. Schirmacher, M. Blessing, E. Fattori, G. Ciliberto, K.H. Meyer zum Buschenfelde, and S. Rose-John. 1997. Soluble IL-6 receptor leads to a paracrine modulation of the IL-6-induced hepatic acute phase response in double transgenic mice. *J. Immunol.* 159:1474–1481.